X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SUN PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SUN PHARMA ASTRAZENECA PHARMA/
SUN PHARMA
 
P/E (TTM) x 91.9 15.3 601.8% View Chart
P/BV x 13.1 3.6 364.6% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ASTRAZENECA PHARMA   SUN PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
SUN PHARMA
Mar-16
ASTRAZENECA PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2851,201 107.0%   
Low Rs634706 89.8%   
Sales per share (Unadj.) Rs189.6117.5 161.4%  
Earnings per share (Unadj.) Rs-0.219.6 -1.0%  
Cash flow per share (Unadj.) Rs3.823.8 16.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs68.6130.5 52.6%  
Shares outstanding (eoy) m25.002,406.60 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.18.1 62.3%   
Avg P/E ratio x-4,712.748.7 -9,684.7%  
P/CF ratio (eoy) x249.640.1 623.1%  
Price / Book Value ratio x14.07.3 191.3%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m23,9882,294,813 1.0%   
No. of employees `0001.614.7 10.6%   
Total wages/salary Rs m1,60547,971 3.3%   
Avg. sales/employee Rs Th3,040.219,169.8 15.9%   
Avg. wages/employee Rs Th1,029.23,253.0 31.6%   
Avg. net profit/employee Rs Th-3.33,197.9 -0.1%   
INCOME DATA
Net Sales Rs m4,740282,697 1.7%  
Other income Rs m926,170 1.5%   
Total revenues Rs m4,832288,867 1.7%   
Gross profit Rs m-13083,239 -0.2%  
Depreciation Rs m10110,135 1.0%   
Interest Rs m04,769 0.0%   
Profit before tax Rs m-13974,505 -0.2%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m139-6,852 -2.0%   
Tax Rs m59,349 0.1%   
Profit after tax Rs m-547,159 -0.0%  
Gross profit margin %-2.729.4 -9.3%  
Effective tax rate %-3.712.5 -29.2%   
Net profit margin %-0.116.7 -0.6%  
BALANCE SHEET DATA
Current assets Rs m2,726308,646 0.9%   
Current liabilities Rs m2,435132,477 1.8%   
Net working cap to sales %6.162.3 9.9%  
Current ratio x1.12.3 48.1%  
Inventory Days Days7483 88.9%  
Debtors Days Days4188 46.5%  
Net fixed assets Rs m1,035133,606 0.8%   
Share capital Rs m502,407 2.1%   
"Free" reserves Rs m942266,909 0.4%   
Net worth Rs m1,716314,042 0.5%   
Long term debt Rs m031,167 0.0%   
Total assets Rs m4,156542,196 0.8%  
Interest coverage xNM16.6-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.10.5 218.7%   
Return on assets %-0.19.6 -1.3%  
Return on equity %-0.315.0 -2.0%  
Return on capital %017.8 0.0%  
Exports to sales %5.714.0 40.7%   
Imports to sales %6.53.1 205.7%   
Exports (fob) Rs m27039,572 0.7%   
Imports (cif) Rs m3068,882 3.4%   
Fx inflow Rs m37542,171 0.9%   
Fx outflow Rs m47021,583 2.2%   
Net fx Rs m-9620,588 -0.5%   
CASH FLOW
From Operations Rs m-867,694 -0.0%  
From Investments Rs m-146-44,549 0.3%  
From Financial Activity Rs m862-19,243 -4.5%  
Net Cashflow Rs m7093,902 18.2%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.1 5.8%  
FIIs % 15.7 23.0 68.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.3 109.6%  
Shareholders   12,856 133,026 9.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  CADILA HEALTHCARE  GSK PHARMA  PLETHICO PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS